Hon-Ren Huang, Ph.D.

Senior Director of Biology

Before joining Carmine Therapeutics, Dr. Huang was leading CRISPR/AAV-mediated targeted gene insertion efforts at Intellia Therapeutics. Together with Regeneron, his team successfully advanced a hemophilia program from a mouse model to non-human primate studies, which led to the expansion of collaboration.

Prior to Intellia Therapeutics, Dr. Huang worked for Constellation Pharmaceuticals in Cambridge, Massachusetts for five years, advancing the chemical biology approach to interrogate the whole bromodomain protein family with Genentech researchers. He has published 12 peer-reviewed papers and has 8 patents and patent applications.

Dr. Huang received his Ph.D. from the University of Texas Southwestern Medical Center. He completed his post-doctoral training in the laboratory of Prof. Tom Maniatis at Harvard University.

© 2020 - 2021 Carmine Therapeutics, Inc.

All Rights Reserved.

an

VENTURES X_EVX_INTL LOGO-FINAL-VENTURES.

Company